Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | HPGD | P15428 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.57 |
| ▸ | EP300 | Q09472 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 6/20 | 0.44 |
| ▸ | GLA | P06280 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | CASP1 | P29466 | 3/20 | 0.42 |
| ▸ | CASP7 | P55210 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351705 | 0.88 | ALDH1A1 (0.69) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL37694 | 0.88 | ALDH1A1 (0.69) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| Ethylene SCHEMBL28055534 | 0.86 | ALDH1A1 (0.67) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| Acetic Acid SCHEMBL4964004 | 0.84 | KDM4E (0.43) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL28649238 | 0.81 | ALDH1A1 (0.71) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL13869309 | 0.76 | ALDH1A1 (0.86) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL808511 | 0.75 | ALDH1A1 (0.73) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL26978514 | 0.75 | ALDH1A1 (0.69) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL8132354 | 0.74 | ALDH1A1 (1.00) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL5590828 | 0.74 | ALDH1A1 (0.78) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210275693-A1 | MODIFIED WOUND DRESSINGS | CONVATEC TECHNOLOGIES INC. | 2021-09-09 | — | — | US | claimed |
| US-20190307904-A1 | MODIFIED WOUND DRESSINGS | CONVATEC TECHNOLOGIES INC (US) | 2019-10-10 | — | — | US | claimed |
| EP-3436012-A1 | MODIFIED WOUND DRESSINGS | ConvaTec Technologies Inc. (US) | 2019-02-06 | — | — | EP | claimed |
| WO-2017173026-A1 | MODIFIED WOUND DRESSINGS | CONVATEC TECHNOLOGIES INC. (US) | 2017-10-05 | — | — | WO | claimed |
| US-20240123091-A1 | MODIFIED WOUND DRESSINGS | CONVATEC TECHNOLOGIES, INC. | 2024-04-18 | — | — | US | disclosed |
| US-20240083953-A1 | Desmoglein 2 (DSG2) Binding Proteins and Uses Therefor | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2024-03-14 | — | — | US | disclosed |
| WO-2024011121-A2 | TISSUE PROCESSING | APPLIKATE TECHNOLOGIES, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20240011977-A1 | TISSUE PROCESSING | APPLIKATE TECHNOLOGIES, INC. | 2024-01-11 | — | — | US | disclosed |
| US-11865192-B2 | Modified wound dressings | CONVATEC TECHNOLOGIES, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-11820795-B2 | Desmoglein 2 (DSG2) binding proteins and uses therefor | UNIVERSITY OF WASHINGTON (US) | 2023-11-21 | — | — | US | disclosed |
| EP-3436012-B1 | MODIFIED WOUND DRESSINGS | CONVATEC TECHNOLOGIES INC (US) | 2023-09-20 | — | — | EP | disclosed |
| US-11573179-B2 | Tissue processing | APPLIKATE TECHNOLOGIES LLC (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2001079844-A2 | MULTI-ANALYTE DIAGNOSTIC TEST FOR THYROID DISORDERS | BIO-RAD LABORATORIES, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001075163-A2 | HIGH THROUGHPUT METHODS FOR HAPLOTYPING | POLYGENYX, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
| EP-0912597-A4 | NUCLEIC ACID AMPLIFICATION OLIGONUCLEOTIDES WITH MOLECULAR ENERGY TRANSFER LABELS AND METHODS BASED THEREON | INTERGEN COMPANY (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000079009-A2 | IMPROVED PRIMERS AND METHODS FOR THE DETECTION AND DISCRIMINATION OF NUCLEIC ACIDS | INVITROGEN CORPORATION (US) | 2000-12-28 | — | — | WO | disclosed |
| US-6090552-A | DETECTING TELOMERASE ACTIVITY BY CONTACTING SAMPLE WITH PRIMERS, ONE HAVING LABELS AND SUBSTRATE FOR ENZYME, OTHER COMPLEMENTARY TO TELOMERIC REPEATS; ALLOWING ENZYME ACTIVITY; AMPLIFYING NUCLEIC ACIDS; DETECTING/MEASURING EMITTED ENERGY | INTERGEN COMPANY (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0912597-A1 | NUCLEIC ACID AMPLIFICATION OLIGONUCLEOTIDES WITH MOLECULAR ENERGY TRANSFER LABELS AND METHODS BASED THEREON | ONCOR, INC. (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998002449-A9 | NUCLEIC ACID AMPLIFICATION OLIGONUCLEOTIDES WITH MOLECULAR ENERGY TRANSFER LABELS AND METHODS BASED THEREON | — | 1998-04-30 | — | — | WO | disclosed |
| WO-1998002449-A1 | NUCLEIC ACID AMPLIFICATION OLIGONUCLEOTIDES WITH MOLECULAR ENERGY TRANSFER LABELS AND METHODS BASED THEREON | ONCOR, INC. (US) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240123091-A1 | MODIFIED WOUND DRESSINGS | MMP8, CD68, ELANE | ALDH1A1 393/4885KDM4E 2928/4885MAPT 4774/4885 |
| US-20190307904-A1 | MODIFIED WOUND DRESSINGS | MMP8, CD68, ELANE | ALDH1A1 393/4885KDM4E 2928/4885MAPT 4774/4885 |
| US-11865192-B2 | Modified wound dressings | MMP8, CD68, ELANE | ALDH1A1 393/4885KDM4E 2928/4885MAPT 4774/4885 |
| US-20210275693-A1 | MODIFIED WOUND DRESSINGS | MMP8, CD68, ELANE | ALDH1A1 393/4885KDM4E 2928/4885MAPT 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.